spikevax (previously covid-19 vaccine moderna)
moderna biotech spain, s.l. - single-stranded, 5’-capped messenger rna (mrna) produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vaccins - spikevax is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older. spikevax bivalent original/omicron ba. 1 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 years of age and older who have previously received at least a primary vaccination course against covid-19. spikevax bivalent original/omicron ba. 4-5 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older. spikevax xbb. 5 is indicated for active immunisation to prevent covid 19 caused by sars-cov-2 in individuals 6 months of age and older. the use of this vaccine should be in accordance with official recommendations.
comirnaty
biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vaccins - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. het gebruik van dit vaccin moet gebeuren in overeenstemming met officiële aanbevelingen.
gasvormige medische zuurstof, air liquide santé international 100 % inhalatiegas gascilinder (geïntegr. red. vent.)
air liquide santé international s.a. - zuurstof 100 % - inhalatiegas - 100 % - zuurstof 100 % - oxygen
liquide medische zuurstof, air liquide santé international 100 % medicin. gas (vloeib.) cryog. vat, mobiel cryog. vat, vast
air liquide santé international s.a. - zuurstof 100 % - medicinaal gas, vloeibaar gemaakt - 100 % - zuurstof - oxygen
gasvormige medische zuurstof, air liquide santé international 100 % inhalatiegas kader gascilinders
air liquide santé international s.a. - zuurstof 100 % - inhalatiegas - 100 % - zuurstof - oxygen
gasvormige medische zuurstof, air liquide santé international 100 % inhalatiegas gascilinder
air liquide santé international s.a. - zuurstof 100 % - inhalatiegas - 100 % - zuurstof 100 % - oxygen
gasvormige medische zuurstof, air liquide santé international 100 % inhalatiegas gascilinder (geïntegr. red. vent.)
air liquide santé international s.a. - zuurstof 100 % - inhalatiegas - 100 % - zuurstof 100 % - oxygen
medische distikstofoxide sol 100% v/v medicin. gas (vloeib.) gascilinder
sol s.p.a. - distikstofoxide 100 % v/v - medicinaal gas, vloeibaar gemaakt - 100% v/v - distikstofoxide - nitrous oxide
prednisolone 20 mg kela 20 mg tabl.
kela laboratoria - prednisolon 20 mg - tablet - 20 mg - prednisolon 20 mg - hydrocortisone and antiseptics - hond
airapy 21.5 % v/v medicin. gas (samengep.) gascilinder
linde gas therapeutics benelux b.v. - zuurstof 21,5 % v/v - medicinaal gas, samengeperst - zuurstof - medical air